Inhibitor Therapeutics, Inc. (INTI)
OTCMKTS · Delayed Price · Currency is USD
0.0430
-0.0169 (-28.21%)
Sep 16, 2025, 3:35 PM EDT
Inhibitor Therapeutics Company Description
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States.
It engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.
The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019.
Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
Inhibitor Therapeutics, Inc.
| Country | United States |
| Founded | 1992 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Francis O'Donnell |
Contact Details
Address: 3014 West Palmira Avenue Tampa, Delaware 33629-7264 United States | |
| Phone | 813 864 2562 |
| Website | inhibitortx.com |
Stock Details
| Ticker Symbol | INTI |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US45720M1053 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Francis E. O'Donnell Jr., M.D. | Founder, Executive Chairman and Chief Executive Officer |
| James A. McNulty CPA | Interim Chief Financial Officer, Treasurer and Secretary |